The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Open accessAbstract
Myeloproliferative neoplasms (MPNs) originate from genetically transformed hematopoietic stem cells that retain the capacity for multilineage differentiation and effective myelopoiesis. Beginning in early 2005, a number of novel mutations involving Janus kinase 2 (JAK2), Myeloproliferative Leukemia Virus (MPL), TET oncogene family member 2 (TET2), Additional Sex Combs-Like 1 (ASXL1), Casitas B-lineage lymphoma proto-oncogene (CBL), Isocitrate dehydrogenase (IDH) and IKAROS family zinc finger 1 (IKZF1) have been described in BCR-ABL1-negative MPNs. However, none of these mutations were MPN specific, displayed mutual exclusivity or could be traced back to a common ancestral clone. JAK2 and MPL mutations appear to exert a phenotype-modifying effect and are distinctly associated with polycythemia vera, essential thrombocythemia and primary myelofibrosis; the corresponding mutational frequencies are approximately 99, 55 and 65% for JAK2 and 0, 3 and 10% for MPL mutations. The incidence of TET2, ASXL1, CBL, IDH or IKZF1 mutations in these disorders ranges from 0 to 17%; these latter mutations are more common in chronic (TET2, ASXL1, CBL) or juvenile (CBL) myelomonocytic leukemias, mastocytosis (TET2), myelodysplastic syndromes (TET2, ASXL1) and secondary acute myeloid leukemia, including blast-phase MPN (IDH, ASXL1, IKZF1). The functional consequences of MPN-associated mutations include unregulated JAK-STAT (Janus kinase/signal transducer and activator of transcription) signaling, epigenetic modulation of transcription and abnormal accumulation of oncoproteins. However, it is not clear as to whether and how these abnormalities contribute to disease initiation, clonal evolution or blastic transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1
Lee, S.-W., Cho, Y.-S., Na, J.-M., Park, U., Kang, M., Kim, E., & Um, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.065862 · Cited by 93
RetractedAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276
Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationThe JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Self-citationAnalysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., El Hallani, S., Boisselier, B., Mokhtari, K., Hoang-Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,008
Tefferi, A., & Vardiman, J. W. (2008) · Leukemia · doi:10.1038/sj.leu.2404955 · Cited by 1,002
Self-citationTefferi, A., Thiele, J., Orazi, A., Kvasnicka, H. M., Barbui, T., Hanson, C. A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 862
Self-citationWick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0715 · Cited by 711
Acquired mutations in TET2 are common in myelodysplastic syndromes
Langemeijer, S. M. C., Kuiper, R. P., Berends, M., Knops, R., Aslanyan, M. G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A. G., Raymakers, R. A. P., et al. (2009) · Nature Genetics · doi:10.1038/ng.391 · Cited by 680
Tefferi, A., & Vardiman, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902908 · Cited by 670
Self-citationCampbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 653
Polycythemia Vera: Stem-Cell and Probable Clonal Origin of the Disease
Adamson, J. W., Fialkow, P. J., Murphy, S., Prchal, J. F., & Steinmann, L. (1976) · New England Journal of Medicine · doi:10.1056/nejm197610212951702 · Cited by 640
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Dawson, M. A., Bannister, A. J., Göttgens, B., Foster, S. D., Bartke, T., Green, A. R., & Kouzarides, T. (2009) · Nature · doi:10.1038/nature08448 · Cited by 622
Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., Schackert, G., Simon, M., Tonn, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0805 · Cited by 614
Gelsi‐Boyer, V., Trouplin, V., Adélaïde, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07697.x · Cited by 564
Jacobson, R., Salo, A., & Fialkow, P. (1978) · Blood · doi:10.1182/blood.v51.2.189.189 · Cited by 493
Steensma, D. P., Dewald, G. W., Lasho, T. L., Powell, H. L., McClure, R. F., Levine, R. L., Gilliland, D. G., & Tefferi, A. (2005) · Blood · doi:10.1182/blood-2005-03-1183 · Cited by 466
Self-citationVannucchi, A. M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R. M., Finazzi, G., Guerini, V., Fabris, F., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064287 · Cited by 449
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Tiedt, R., Hao-Shen, H., Sobas, M. A., Looser, R., Dirnhofer, S., Schwaller, J., & Skoda, R. C. (2008) · Blood · doi:10.1182/blood-2007-08-107748 · Cited by 440
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
Beer, P. A., Campbell, P. J., Scott, L. M., Bench, A. J., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Hasselbalch, H. C., Bowman, R., et al. (2008) · Blood · doi:10.1182/blood-2008-01-131664 · Cited by 431
Tefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Self-citationLorsbach, R. B., Moore, J., Mathew, S., Raimondi, S. C., Mukatira, S. T., & Downing, J. R. (2003) · Leukemia · doi:10.1038/sj.leu.2402834 · Cited by 416
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Sanada, M., Suzuki, T., Shih, L.-Y., Otsu, M., Kato, M., Yamazaki, S., Tamura, A., Honda, H., Sakata-Yanagimoto, M., Kumano, K., et al. (2009) · Nature · doi:10.1038/nature08240 · Cited by 402
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Jones, A. V., Chase, A., Silver, R. T., Oscier, D., Zoi, K., Wang, Y. L., Cario, H., Pahl, H. L., Collins, A., Reiter, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.334 · Cited by 399
Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
Fialkow, P., Faguet, G., Jacobson, R., Vaidya, K., & Murphy, S. (1981) · Blood · doi:10.1182/blood.v58.5.916.916 · Cited by 386
Grand, F. H., Hidalgo-Curtis, C. E., Ernst, T., Zoi, K., Zoi, C., McGuire, C., Kreil, S., Jones, A., Score, J., Metzgeroth, G., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194548 · Cited by 378
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Longo, G., Pancrazzi, A., Ponziani, V, Bogani, C., Ferrini, P. R., Rambaldi, A., Guerini, V, et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404854 · Cited by 368
Bleeker, F. E., Lamba, S., Leenstra, S., Troost, D., Hulsebos, T., Vandertop, W. P., Frattini, M., Molinari, F., Knowles, M., Cerrato, A., et al. (2009) · Human Mutation · doi:10.1002/humu.20937 · Cited by 363
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Olcaydu, D., Harutyunyan, A., Jäger, R., Berg, T., Gisslinger, B., Pabinger, I., Gisslinger, H., & Kralovics, R. (2009) · Nature Genetics · doi:10.1038/ng.341 · Cited by 362
Mutations of ASXL1 gene in myeloproliferative neoplasms
Carbuccia, N., Murati, A., Trouplin, V, Brecqueville, M., Adélaïde, J., Rey, J., Vainchenker, W., Bernard, O. A., Chaffanet, M., Vey, N., et al. (2009) · Leukemia · doi:10.1038/leu.2009.141 · Cited by 331
Jankowska, A. M., Szpurka, H., Tiu, R. V., Makishima, H., Afable, M., Huh, J., O'Keefe, C. L., Ganetzky, R., McDevitt, M. A., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2009-02-205690 · Cited by 331
Theocharides, A., Boissinot, M., Girodon, F., Garand, R., Teo, S.-S., Lippert, E., Talmant, P., Tichelli, A., Hermouet, S., & Skoda, R. C. (2007) · Blood · doi:10.1182/blood-2006-12-062125 · Cited by 326
Abdel-Wahab, O., Manshouri, T., Patel, J., Harris, K., Yao, J., Hedvat, C., Heguy, A., Bueso-Ramos, C., Kantarjian, H., Levine, R. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3783 · Cited by 326
Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., & Lodish, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509714102 · Cited by 316
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Kang, M. R., Kim, M. S., Oh, J. E., Kim, Y. R., Song, S. Y., Seo, S. I., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24379 · Cited by 313
Two routes to leukemic transformation after a JAK2 mutation–positive myeloproliferative neoplasm
Beer, P. A., Delhommeau, F., LeCouédic, J.-P., Dawson, M. A., Chen, E., Bareford, D., Kušec, R., McMullin, M. F., Harrison, C. N., Vannucchi, A. M., et al. (2010) · Blood · doi:10.1182/blood-2009-08-236596 · Cited by 307
Bleeker, F. E., Atai, N. A., Lamba, S., Jonker, A., Rijkeboer, D., Bosch, K. S., Tigchelaar, W., Troost, D., Vandertop, W. P., Bardelli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0645-6 · Cited by 302
Pietra, D., Li, S., Brisci, A., Passamonti, F., Rumi, E., Theocharides, A., Ferrari, M., Gisslinger, H., Kralovics, R., Cremonesi, L., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101576 · Cited by 298
Pardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404810 · Cited by 298
Self-citationVannucchi, A. M., Antonioli, E., Guglielmelli, P., Pardanani, A., & Tefferi, A. (2008) · Leukemia · doi:10.1038/leu.2008.113 · Cited by 294
Self-citationThe Cbl family proteins: Ring leaders in regulation of cell signaling
Swaminathan, G., & Tsygankov, A. Y. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20694 · Cited by 291
Canonical and non-canonical JAK–STAT signaling
Li, W. X. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.008 · Cited by 290
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
Loh, M. L., Sakai, D. S., Flotho, C., Kang, M., Fliegauf, M., Archambeault, S., Mullighan, C. G., Chen, L., Bergstraesser, E., Bueso-Ramos, C. E., et al. (2009) · Blood · doi:10.1182/blood-2009-01-198416 · Cited by 286
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Green, A., & Beer, P. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0910063 · Cited by 285
Kralovics, R., Teo, S.-S., Li, S., Theocharides, A., Buser, A. S., Tichelli, A., & Skoda, R. C. (2006) · Blood · doi:10.1182/blood-2005-11-009605 · Cited by 278
Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari Syndrome
Patel, R. K., Lea, N. C., Heneghan, M. A., Westwood, N. B., Milojkovic, D., Thanigaikumar, M., Yallop, D., Arya, R., Pagliuca, A., Gäken, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.008 · Cited by 277
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguié, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215814 · Cited by 276
Pardanani, A., Hood, J., Lasho, T., Levine, R. L., Martin, M. B., Noronha, G., Finke, C., Mak, C. C., Mesa, R., Zhu, H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404750 · Cited by 272
Self-citationTefferi, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Patnaik, M. M., Hanson, C. A., Pardanani, A., Gilliland, D. G., & Levine, R. L. (2009) · Leukemia · doi:10.1038/leu.2009.59 · Cited by 268
Self-citationThrombosis in primary myelofibrosis: incidence and risk factors
Barbui, T., Carobbio, A., Cervantes, F., Vannucchi, A. M., Guglielmelli, P., Antonioli, E., Alvarez-Larrán, A., Rambaldi, A., Finazzi, G., & Barosi, G. (2010) · Blood · doi:10.1182/blood-2009-08-238956 · Cited by 266
Landgren, O., Goldin, L. R., Kristinsson, S. Y., Helgadottir, E. A., Samuelsson, J., & Björkholm, M. (2008) · Blood · doi:10.1182/blood-2008-03-143602 · Cited by 261
Barosi, G., Bergamaschi, G., Marchetti, M., Vannucchi, A. M., Guglielmelli, P., Antonioli, E., Massa, M., Rosti, V., Campanelli, R., Villani, L., et al. (2007) · Blood · doi:10.1182/blood-2007-07-099184 · Cited by 258
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
Tefferi, A., Levine, R. L., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Finke, C. M., Mullally, A., Li, C.-Y., Pardanani, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.37 · Cited by 252
Self-citationTefferi, A., Lasho, T. L., Huang, J., Finke, C., Mesa, R. A., Li, C. Y., Wu, W., Hanson, C. A., & Pardanani, A. (2008) · Leukemia · doi:10.1038/sj.leu.2405097 · Cited by 251
Self-citationAkada, H., Yan, D., Zou, H., Fiering, S., Hutchison, R. E., & Mohi, M. G. (2010) · Blood · doi:10.1182/blood-2009-04-215848 · Cited by 249
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
Kosmider, O., Gelsi-Boyer, V., Ciudad, M., Racoeur, C., Jooste, V., Vey, N., Quesnel, B., Fenaux, P., Bastie, J.-N., Beyne-Rauzy, O., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.011205 · Cited by 247
Passamonti, F., Elena, C., Schnittger, S., Skoda, R. C., Green, A. R., Girodon, F., Kiladjian, J.-J., McMullin, M. F., Ruggeri, M., Besses, C., et al. (2011) · Blood · doi:10.1182/blood-2010-11-316810 · Cited by 236
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
Campbell, P. J. (2006) · Blood · doi:10.1182/blood-2005-08-3395 · Cited by 224
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Guerini, V., Barosi, G., Ruggeri, M., Specchia, G., Lo-Coco, F., Delaini, F., et al. (2008) · Blood · doi:10.1182/blood-2008-01-135897 · Cited by 222
The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera
Tefferi, A., Lasho, T. L., Schwager, S. M., Strand, J. S., Elliott, M., Mesa, R., Li, C., Wadleigh, M., Lee, S. J., & Gilliland, D. G. (2006) · Cancer · doi:10.1002/cncr.21645 · Cited by 221
Self-citationMakishima, H., Cazzolli, H., Szpurka, H., Dunbar, A., Tiu, R., Huh, J., Muramatsu, H., O'Keefe, C., Hsi, E., Paquette, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7503 · Cited by 218
Guglielmelli, P., Barosi, G., Specchia, G., Rambaldi, A., Lo Coco, F., Antonioli, E., Pieri, L., Pancrazzi, A., Ponziani, V., Delaini, F., et al. (2009) · Blood · doi:10.1182/blood-2009-04-216044 · Cited by 215
Flt3-dependent transformation by inactivating c-Cbl mutations in AML
Sargin, B., Choudhary, C., Crosetto, N., Schmidt, M. H. H., Grundler, R., Rensinghoff, M., Thiessen, C., Tickenbrock, L., Schwäble, J., Brandts, C., et al. (2007) · Blood · doi:10.1182/blood-2007-01-066076 · Cited by 213
Pardanani, A. (2008) · Leukemia · doi:10.1038/sj.leu.2404948 · Cited by 212
Tefferi, A., Lasho, T. L., Schwager, S. M., Steensma, D. P., Mesa, R. A., Li, C., Wadleigh, M., & Gary Gilliland, D. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05776.x · Cited by 207
Self-citationPardanani, A., Lasho, T., Smith, G., Burns, C. J., Fantino, E., & Tefferi, A. (2009) · Leukemia · doi:10.1038/leu.2009.50 · Cited by 207
Self-citationChou, W.-C., Hou, H.-A., Chen, C.-Y., Tang, J.-L., Yao, M., Tsay, W., Ko, B.-S., Wu, S.-J., Huang, S.-Y., Hsu, S.-C., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253070 · Cited by 204
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
Pardanani, A., Lasho, T. L., Finke, C. M., Mai, M., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.77 · Cited by 184
Self-citationPlo, I., Nakatake, M., Malivert, L., de Villartay, J.-P., Giraudier, S., Villeval, J.-L., Wiesmuller, L., & Vainchenker, W. (2008) · Blood · doi:10.1182/blood-2008-01-134114 · Cited by 177
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
Shide, K., Shimoda, H. K., Kumano, T., Karube, K., Kameda, T., Takenaka, K., Oku, S., Abe, H., Katayose, K. S., Kubuki, Y., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405043 · Cited by 175
Fisher, C. L., Pineault, N., Brookes, C., Helgason, C. D., Ohta, H., Bodner, C., Hess, J. L., Humphries, R. K., & Brock, H. W. (2009) · Blood · doi:10.1182/blood-2009-07-230698 · Cited by 164
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
Guerini, V., Barbui, V., Spinelli, O., Salvi, A., Dellacasa, C. M., Carobbio, A., Introna, M., Barbui, T., Golay, J., & Rambaldi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2405049 · Cited by 160
Schaub, F. X., Looser, R., Li, S., Hao-Shen, H., Lehmann, T., Tichelli, A., & Skoda, R. C. (2010) · Blood · doi:10.1182/blood-2009-09-245381 · Cited by 157
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
Kittur, J., Knudson, R. A., Lasho, T. L., Finke, C. M., Gangat, N., Wolanskyj, A. P., Li, C., Wu, W., Ketterling, R. P., Pardanani, A. D., et al. (2007) · Cancer · doi:10.1002/cncr.22663 · Cited by 157
Self-citationHost genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Pardanani, A. D., Fridley, B. L., Lasho, T. L., Gilliland, D. G., & Tefferi, A. (2007) · Blood · doi:10.1182/blood-2007-06-095703 · Cited by 153
Self-citationAnaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation
Guglielmelli, P., Pancrazzi, A., Bergamaschi, G., Rosti, V., Villani, L., Antonioli, E., Bosi, A., Barosi, G., & Vannucchi, A. M. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06565.x · Cited by 153
Steensma, D. P., McClure, R. F., Karp, J. E., Tefferi, A., Lasho, T. L., Powell, H. L., Dewald, G., & Kaufmann, S. H. (2006) · Leukemia · doi:10.1038/sj.leu.2404206 · Cited by 148
Self-citationDeletions of the transcription factor Ikaros in myeloproliferative neoplasms
Jäger, R., Gisslinger, H., Passamonti, F., Rumi, E., Berg, T., Gisslinger, B., Pietra, D., Harutyunyan, A. S., Klampfl, T., Olcaydu, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.99 · Cited by 148
Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis
Moliterno, A. R., Williams, D. M., Gutierrez‐Alamillo, L., Salvatori, R., Ingersoll, R., & Spivak, J. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404241101 · Cited by 139
The complete evaluation of erythrocytosis: congenital and acquired
Patnaik, M. M., & Tefferi, A. (2009) · Leukemia · doi:10.1038/leu.2009.54 · Cited by 135
Self-citationIsocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas
Gaal, J., Burnichon, N., Korpershoek, E., Roncelin, I., Bertherat, J. Y., Plouin, P., de Krijger, R. R., Gimenez‐Roqueplo, A., & Dinjens, W. N. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2170 · Cited by 131
Reindl, C., Quentmeier, H., Petropoulos, K., Greif, P. A., Benthaus, T., Argiropoulos, B., Mellert, G., Vempati, S., Duyster, J., Buske, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1325 · Cited by 123
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias
Carbuccia, N., Trouplin, V., Gelsi‐Boyer, V., Murati, A., Rocquain, J., Adélaı̈de, J., Olschwang, S., Xerri, L., Vey, N., Chaffanet, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.218 · Cited by 121
Schmitt-Graeff, A. H., Teo, S.-S., Olschewski, M., Schaub, F. X., Haxelmans, S., Kirn, A., Reinecke, P., Germing, U., & Skoda, R. C. (2007) · Haematologica · doi:10.3324/haematol.11581 · Cited by 121
Chaligné, R., Tonetti, C., Besancenot, R., Roy, L., Marty, C., Mossuz, P., Kiladjian, J., Socié, G., Bordessoule, D., Bousse-Kerdilès, M. L., et al. (2008) · Leukemia · doi:10.1038/leu.2008.137 · Cited by 121
Muramatsu, H., Makishima, H., Jankowska, A. M., Cazzolli, H., O’Keefe, C. L., Yoshida, N., Xu, Y., Nishio, N., Hama, A., Yagasaki, H., et al. (2009) · Blood · doi:10.1182/blood-2009-06-226340 · Cited by 118
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science
Kilpivaara, O., & Levine, R. L. (2008) · Leukemia · doi:10.1038/leu.2008.229 · Cited by 115
Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma
Gravendeel, L. A. M., Kloosterhof, N. K., Bralten, L. B. C., van Marion, R., Dubbink, H. J., Dinjens, W. N. M., Bleeker, F. E., Hoogenraad, C. C., Michiels, E. M. C., Kros, J. M., et al. (2010) · Human Mutation · doi:10.1002/humu.21201 · Cited by 111
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis.
Chaligné, R., James, C., Tonetti, C., Besancenot, R., Couédic, J. L., Fava, F., Mazurier, F., Godin, I., Maloum, K., Larbret, F., et al. (2007) · Blood · doi:10.1182/blood-2007-05-089003 · Cited by 109
James, C., Mazurier, F., Dupont, S., Chaligné, R., Lamrissi‐Garcia, I., Tulliez, M., Lippert, É., Mahon, F., Pasquet, J., Étienne, G., et al. (2008) · Blood · doi:10.1182/blood-2008-02-137877 · Cited by 108
Tefferi, A., Lasho, T. L., Patnaik, M. M., Finke, C. M., Hussein, K., Hogan, W. J., Elliott, M. A., Litzow, M. R., Hanson, C. A., & Pardanani, A. D. (2009) · Leukemia · doi:10.1038/leu.2009.225 · Cited by 105
Self-citationThe history of myeloproliferative disorders: before and after Dameshek
Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404946 · Cited by 102
Self-citationUbiquitination and degradation of the thrombopoietin receptor c-Mpl
Saur, S. J., Sangkhae, V., Geddis, A. E., Kaushansky, K., & Hitchcock, I. S. (2009) · Blood · doi:10.1182/blood-2009-06-227033 · Cited by 98
Conventional cytogenetics in myelofibrosis: literature review and discussion
Hussein, K., Dyke, D. L. V., & Tefferi, A. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01224.x · Cited by 97
Self-citationGenetic complexity of myeloproliferative neoplasms
Královics, R. (2008) · Leukemia · doi:10.1038/leu.2008.233 · Cited by 89
An, Q., Wright, S. L., Konn, Z. J., Matheson, E. C., Minto, L., Moorman, A. V., Parker, H., Griffiths, M., Ross, F. M., Davies, T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803494105 · Cited by 87
Teofili, L., Giona, F., Torti, L., Cenci, T., Ricerca, B. M., Rumi, C., Nunes, V., Foà, R., Leone, G. G. M., Martini, M., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.007542 · Cited by 86
Beer, P. A., Jones, A. V., Bench, A. J., Goday‐Fernández, A., Boyd, E. M., Vaghela, K. J., Erber, W. N., Odeh, B., Wright, C., McMullin, M. F., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07560.x · Cited by 86
Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients
Butcher, C. M., Hahn, U., To, L. B., Gécz, J., Wilkins, E. J., Scott, H. S., Bardy, P., & D’Andrea, R. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404971 · Cited by 85
Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic Syndrome
Mohamedali, A. M., Smith, A., Gäken, J. A., Lea, N. C., Mian, S. A., Westwood, N., Strupp, C., Gattermann, N., Germing, U., & Mufti, G. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6985 · Cited by 84
JAK redux: a second look at the regulation and role of JAKs in the heart
Kurdi, M., & Booz, G. W. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00032.2009 · Cited by 84
Funakoshi‐Tago, M., Tago, K., Abe, M., Sonoda, Y., & Kasahara, T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.040733 · Cited by 81
Pecquet, C., Staerk, J., Chaligné, R., Goss, V. L., Lee, K. A., Zhang, X., Rush, A. J., Hees, J. V., Poirel, H. A., Scheiff, J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-183558 · Cited by 81
Abbas, S., Rotmans, G., Löwenberg, B., & Valk, P. J. M. (2008) · Haematologica · doi:10.3324/haematol.13187 · Cited by 74
Aberrant signal transduction pathways in myeloproliferative neoplasms
Kota, J., Cáceres, N. E., & Constantinescu, S. N. (2008) · Leukemia · doi:10.1038/leu.2008.236 · Cited by 73
Pardanani, A. D., Lasho, T. L., Finke, C. M., Mesa, R. A., Hogan, W. J., Ketterling, R. P., Gilliland, D. G., & Tefferi, A. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0175 · Cited by 72
Self-citationSchaub, F. X., Jäger, R., Looser, R., Hao-Shen, H., Hermouet, S., Girodon, F., Tichelli, A., Gisslinger, H., Královics, R., & Skoda, R. C. (2008) · Blood · doi:10.1182/blood-2008-07-167056 · Cited by 71
Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement?
Viguié, F., Aboura, A., Bouscary, D., Ramond, S., Delmer, A. J., Tachdjian, G., Marie, J., & Casadevall, N. (2005) · Leukemia · doi:10.1038/sj.leu.2403818 · Cited by 69
Pardanani, A. D., Lasho, T. L., Finke, C. M., Gangat, N., Wolanskyj, A. P., Hanson, C. A., & Tefferi, A. (2009) · Leukemia · doi:10.1038/leu.2009.226 · Cited by 69
Self-citationMutation in TET2 in Myeloid Cancers
(2009) · New England Journal of Medicine · doi:10.1056/nejmc091348 · Cited by 66
Self-citationChronic myeloproliferative diseases with concurrent BCR–ABL junction and JAK2V617F mutation
Hussein, K., Bock, O., Theophile, K., Seegers, A., Arps, H., Basten, O., Grips, K., Franz-Werner, J., Büsche, G., & Kreipe, H. H. (2007) · Leukemia · doi:10.1038/sj.leu.2404993 · Cited by 62
Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias
Couronné, L., Lippert, É., Andrieux, J., Kosmider, O., Radford‐Weiss, I., Penther, D., Dastugue, N., Mugneret, F., Lafage‐Pochitaloff, M., Gachard, N., et al. (2009) · Leukemia · doi:10.1038/leu.2009.169 · Cited by 55
Tefferi, A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00559.x · Cited by 54
Self-citationE3 ligase–defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease
Bandi, S. R., Brandts, C., Rensinghoff, M., Grundler, R., Tickenbrock, L., Köhler, G., Duyster, J., Berdel, W. E., Müller‐Tidow, C., Serve, H. L., et al. (2009) · Blood · doi:10.1182/blood-2008-12-190934 · Cited by 50
Szpurka, H., Gondek, L. P., Mohan, S. R., Hsi, E. D., Theil, K. S., & Maciejewski, J. P. (2008) · Leukemia · doi:10.1038/leu.2008.249 · Cited by 49
A progenitor cell origin of myeloid malignancies
Haeno, H., Levine, R. L., Gilliland, D. G., & Michor, F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908107106 · Cited by 47
Flach, J., Dicker, F., Schnittger, S., Kohlmann, A., Haferlach, T., & Haferlach, C. (2009) · Haematologica · doi:10.3324/haematol.2009.013631 · Cited by 46
Fu, J., Hsu, J., Tang, T., & Shih, L. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10204 · Cited by 43
JAK2 (V617F) mutation in healthy individuals
Passamonti, F., Rumi, E., Pietra, D., Lazzarino, M., & Cazzola, M. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06483.x · Cited by 42
MPLW515L mutation in acute megakaryoblastic leukaemia
Hussein, K., Bock, O., Theophile, K., Schulz-Bischof, K., Porwit‐MacDonald, A., Schlué, J., Jonigk, D. D., & Kreipe, H. (2009) · Leukemia · doi:10.1038/leu.2008.371 · Cited by 41
Lambert, J., Everington, T., Linch, D. C., & Gale, R. E. (2009) · Blood · doi:10.1182/blood-2009-03-209916 · Cited by 40
Mullighan, C. G., & Downing, J. R. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190801947500 · Cited by 33
Paulsson, K. M., Haferlach, C., Fonatsch, C., Hagemeijer, A., Andersen, M. K., Slovak, M., & Johansson, B. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq024 · Cited by 30
Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms
Hussein, K., Abdel-Wahab, O. I., Lasho, T. L., Dyke, D. L. V., Levine, R. L., Hanson, C. A., Pardanani, A. D., & Tefferi, A. (2009) · American Journal of Hematology · doi:10.1002/ajh.21562 · Cited by 28
Self-citationMonte-Mór, B. D. C. R., Plo, I., da Cunha, A. F., Costa, G., de Albuquerque, D. M., Jedidi, A., Villeval, J., Badaoui, S., Lorand-Metze, I. G. H., Pagnano, K. B. B., et al. (2008) · Leukemia · doi:10.1038/leu.2008.275 · Cited by 23
Absence of IDH2 codon 172 mutation in common human cancers
Park, S. W., Chung, N. G., Han, J. Y., Eom, H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24647 · Cited by 19
Jäger, R., Gisslinger, H., Berg, T., Passamonti, F., Cazzola, M., Rumi, E., Pietra, D., Gisslinger, B., Klampfl, T., Harutyunyan, A. S., et al. (2009) · Blood · doi:10.1182/blood.v114.22.435.435 · Cited by 12
Cited by
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2446 · Cited by 1,055
Self-citationEvolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Ko, M., Bandukwala, H. S., An, J., Lamperti, E. D., Thompson, E. C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S. B., & Rao, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112317108 · Cited by 616
Tefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T., & Pardanani, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.9490 · Cited by 608
Self-citation
Metadata
- Authors
- Tefferi, A.
- Venue
- Leukemia
- Published
- 2010-04-29
- Volume
- 24
- Issue
- 6
- Pages
- 1128-1138
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2028803880
- Cited by
- 534
- References
- 150
- FWCI
- 28.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.